• Cereno Scientific shareholders will vote December 15, 2026, on proposals enabling a rights issue of units worth approximately SEK 400 million.
• The board proposes amending share capital and share count limits, alongside authorization to issue shares and warrants.
• Proceeds would primarily fund the global Phase IIb EPIMODE study with CS1; full subscription would support financial sustainability into first-quarter 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cereno Scientific AB published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.